Vanguard Capital Management
ANRO icon

Vanguard Capital Management’s Alto Neuroscience ANRO Stock Holding History

Vanguard Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.7M Buy
1,389,477
+182,452
+15% +$4.22M ﹤0.01% 2112
2026
Q1 		$27.1M Buy
+1,207,025
New +$22.4M ﹤0.01% 2181

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Vanguard Capital Management's ANRO Position: Q2 2026 in Review

Vanguard Capital Management increased its Alto Neuroscience (ANRO) stake by 15% in Q2 2026, buying an estimated $4.22M and bringing the position to 1,389,477 shares worth $36.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2112.

Vanguard Capital Management first reported a position in ANRO in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Vanguard Capital Management held 1,389,477 shares of Alto Neuroscience worth $36.7M as of Q2 2026.
  • Vanguard Capital Management bought 182,452 Alto Neuroscience shares in Q2 2026, an estimated $4.22M.
  • Alto Neuroscience made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2112 holding.
  • Vanguard Capital Management first reported a position in Alto Neuroscience in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.